Olumiant (baricitinib) vs Opzelura (ruxolitinib)

Olumiant (baricitinib) and Opzelura (ruxolitinib) are both Janus kinase (JAK) inhibitors, but they are approved for different conditions. Olumiant is an oral medication primarily approved for the treatment of adults with moderate to severe rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) blockers, and has also received Emergency Use Authorization (EUA) by the FDA for COVID-19 in hospitalized adults. In contrast, Opzelura is a topical cream approved for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (eczema) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. When deciding which medicine is right for an individual, it is important to consider the condition being treated, the route of administration (oral for Olumiant vs. topical for Opzelura), and the specific indications approved by the regulatory authorities, as well as the patient's overall health profile and any other medications they are taking.

Difference between Olumiant and Opzelura

Metric	Olumiant (baricitinib)	Opzelura (ruxolitinib)
Generic name	Baricitinib	Ruxolitinib
Indications	Rheumatoid arthritis, COVID-19 (under Emergency Use Authorization)	Atopic dermatitis
Mechanism of action	JAK inhibitor, anti-inflammatory	JAK inhibitor, anti-inflammatory
Brand names	Olumiant	Opzelura
Administrative route	Oral	Topical
Side effects	Upper respiratory tract infections, nausea, increased cholesterol levels, headache	Application site reactions, headache, urinary tract infections
Contraindications	Severe liver impairment, active serious infections	None known specifically; caution in patients with infections or those using other immunosuppressive drugs
Drug class	JAK inhibitor	JAK inhibitor
Manufacturer	Eli Lilly and Company	Incyte Corporation

Efficacy

Olumiant (Baricitinib) Efficacy in Atopic Dermatitis

Olumiant (baricitinib) is an oral medication that has been shown to be effective in treating moderate-to-severe atopic dermatitis in adults. As a Janus kinase (JAK) inhibitor, baricitinib works by interfering with the pathway that leads to inflammation. Clinical trials have demonstrated that patients with atopic dermatitis who were treated with baricitinib experienced significant improvements in their symptoms, including reduced itchiness and clearer skin. The efficacy of baricitinib for atopic dermatitis was evaluated in several pivotal trials, including BREEZE-AD1 and BREEZE-AD2, which supported its approval for this indication.

Patients treated with baricitinib often see a reduction in the extent and severity of their skin lesions. The drug has been found to be effective as both monotherapy and in combination with topical corticosteroids. The improvements in skin condition have been measured using the Eczema Area and Severity Index (EASI) score, with baricitinib-treated patients showing significant reductions in EASI scores compared to placebo.

Opzelura (Ruxolitinib) Efficacy in Atopic Dermatitis

Opzelura (ruxolitinib) is a topical formulation of a JAK inhibitor used to treat mild-to-moderate atopic dermatitis in non-immunocompromised patients aged 12 years and older. As a topical treatment, ruxolitinib offers a localized approach to inhibiting the JAK-STAT pathway, which is involved in the inflammatory process of atopic dermatitis. Clinical studies have shown that Opzelura can lead to significant improvements in atopic dermatitis symptoms, with patients reporting reduced itch and better sleep quality.

The efficacy of Opzelura in atopic dermatitis was demonstrated in clinical trials, including the TRuE-AD1 and TRuE-AD2 studies. These studies revealed that patients using ruxolitinib cream achieved a greater reduction in itch and an improvement in the Investigator's Global Assessment (IGA) score, which reflects the overall severity of atopic dermatitis, compared to those using a placebo. Additionally, the treatment has been associated with a favorable safety profile, making it a viable option for patients seeking topical therapy for atopic dermatitis.

Regulatory Agency Approvals

Olumiant

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Therapeutic Goods Administration (TGA), Australia

Opzelura

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA

Access Olumiant or Opzelura today

If Olumiant or Opzelura are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Olumiant

Buy Opzelura

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: